Elkamhawy A, Ammar U, Kim M, Gul A, Park T, Lee K
Arch Pharm Res. 2025; 48(2):150-165.
PMID: 39920399
PMC: 11861015.
DOI: 10.1007/s12272-025-01533-5.
Wan X, Yap J, Chen J, Li Y, Faruk R, Tan N
Theranostics. 2025; 15(5):2035-2051.
PMID: 39897565
PMC: 11780520.
DOI: 10.7150/thno.103958.
Li W, Shi X, Tan C, Jiang Z, Li M, Ji Z
Nat Chem Biol. 2025; .
PMID: 39870764
DOI: 10.1038/s41589-024-01826-8.
Fu H, Mo X, Ivanov A
Nat Rev Cancer. 2025; 25(3):189-208.
PMID: 39810024
DOI: 10.1038/s41568-024-00784-6.
Yu H, Xiao G, Gu M, Zhang L, Xia M, Mo S
Proc Natl Acad Sci U S A. 2024; 121(51):e2318871121.
PMID: 39671185
PMC: 11665884.
DOI: 10.1073/pnas.2318871121.
Targeted protein degradation: advances in drug discovery and clinical practice.
Zhong G, Chang X, Xie W, Zhou X
Signal Transduct Target Ther. 2024; 9(1):308.
PMID: 39500878
PMC: 11539257.
DOI: 10.1038/s41392-024-02004-x.
Exploring the Dynamic Interplay of Deleterious Variants on the RAF1-RAP1A Binding in Cancer: Conformational Analysis, Binding Free Energy, and Essential Dynamics.
Khan A, Ali S, Zahid M, Abdelsalam S, Albekairi N, Al-Zoubi R
Proteins. 2024; 93(3):684-701.
PMID: 39498560
PMC: 11809134.
DOI: 10.1002/prot.26759.
Exploration of the shared gene signatures and molecular mechanisms between Alzheimer's disease and intracranial aneurysm.
Liu J, Yin X, Dong Y
Sci Rep. 2024; 14(1):24628.
PMID: 39427050
PMC: 11490550.
DOI: 10.1038/s41598-024-75694-6.
Claudin-4 remodeling of nucleus-cell cycle crosstalk maintains ovarian tumor genome stability and drives resistance to genomic instability-inducing agents.
Villagomez F, Lang J, Nunez-Avellaneda D, Behbakht K, Dimmick H, Webb P
bioRxiv. 2024; .
PMID: 39282307
PMC: 11398366.
DOI: 10.1101/2024.09.04.611120.
Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage.
Zerbib J, Ippolito M, Eliezer Y, De Feudis G, Reuveni E, Savir Kadmon A
Nat Commun. 2024; 15(1):7772.
PMID: 39251587
PMC: 11385192.
DOI: 10.1038/s41467-024-52176-x.
Deciphering the pathogenic role of rare heterozygous missense mutation in the late-presenting DDH.
Liu Y, Fan X, Qian K, Wu C, Zhang L, Yuan L
Front Genet. 2024; 15:1375736.
PMID: 38952713
PMC: 11215071.
DOI: 10.3389/fgene.2024.1375736.
FAK loss reduces BRAF-induced ERK phosphorylation to promote intestinal stemness and cecal tumor formation.
Gao C, Ge H, Kuan S, Cai C, Lu X, Esni F
Elife. 2024; 13.
PMID: 38921956
PMC: 11208045.
DOI: 10.7554/eLife.94605.
Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study.
Shi Y, Han X, Zhao Q, Zheng Y, Chen J, Yu X
Exp Hematol Oncol. 2024; 13(1):60.
PMID: 38867257
PMC: 11167782.
DOI: 10.1186/s40164-024-00528-0.
Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors.
Rasmussen D, Semonis M, Greene J, Muretta J, Thompson A, Toledo Ramos S
Elife. 2024; 13.
PMID: 38742856
PMC: 11093583.
DOI: 10.7554/eLife.95481.
Modulators of MAPK pathway activity during filamentous growth in Saccharomyces cerevisiae.
Pujari A, Cullen P
G3 (Bethesda). 2024; 14(6).
PMID: 38560781
PMC: 11152069.
DOI: 10.1093/g3journal/jkae072.
Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.
Scardaci R, Berlinska E, Scaparone P, Michelina S, Garbo E, Novello S
Mol Oncol. 2024; 18(6):1355-1377.
PMID: 38362705
PMC: 11161739.
DOI: 10.1002/1878-0261.13605.
Efficacy of chemo-immunotherapy in metastatic -mutated lung cancer: a single-center retrospective data.
Yan N, Zhang H, Guo S, Zhang Z, Xu Y, Xu L
Front Oncol. 2024; 14:1353491.
PMID: 38357200
PMC: 10865094.
DOI: 10.3389/fonc.2024.1353491.
BRAF - a tumour-agnostic drug target with lineage-specific dependencies.
Hanrahan A, Chen Z, Rosen N, Solit D
Nat Rev Clin Oncol. 2024; 21(3):224-247.
PMID: 38278874
PMC: 11857949.
DOI: 10.1038/s41571-023-00852-0.
Ku70 senses cytosolic DNA and assembles a tumor-suppressive signalosome.
Pandey A, Shen C, Feng S, Enosi Tuipulotu D, Ngo C, Liu C
Sci Adv. 2024; 10(4):eadh3409.
PMID: 38277448
PMC: 10816715.
DOI: 10.1126/sciadv.adh3409.
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Bahar M, Kim H, Kim D
Signal Transduct Target Ther. 2023; 8(1):455.
PMID: 38105263
PMC: 10725898.
DOI: 10.1038/s41392-023-01705-z.